More: Advances in Restless Legs Syndrome

Choosing the Appropriate Treatment Regimen for a Patient With Restless Legs Syndrome and Comorbid Conditions CME/CE

Author Information and Disclosures

Release Date: June 25, 2008; Valid for credit through June 25, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

If you have not already done so, Medscape encourages you to take a self-assessment survey on Restless Legs Syndrome prior to engaging in this activity. Based on your answers to the survey, specific activities on RLS will be recommended for you and you will receive CME credit.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Boehringer
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Accurately diagnose RLS in a patient with one or more comorbid illnesses
  2. Evaluate nonpharmacologic and pharmacologic management strategies in a patient with RLS and one or more comorbidities
  3. Identify key factors, such as medication interactions and symptom exacerbation, that need to be taken into account when designing a treatment regime for a patient with RLS and one or more comorbidities
Authors and Disclosures

William G. Ondo, MD
Disclosure: William G. Ondo, MD, has disclosed that he has received grants for educational activities from Boehringer Ingelheim, GlaxoSmithKline, Allergan, Teva Pharmaceuticals, and Valeant Pharmaceuticals. Dr. Ondo has also disclosed that he has served as an advisor or consultant to Boehringer Ingelheim, GlaxoSmithKline, Allergan, and Teva Pharmaceuticals.


Carol Peckham
Disclosure: Carol Peckham has disclosed no relevant financial relationships.


Stephanie Kushner
Disclosure: Stephanie Kushner is a member of the professional editorial group at Medscape and has reported no financial relationships relevant to the development of CME activities.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.